You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

mass. movers

Aegerion climbs a second straight day

Aegerion’s Juxtapid drug is used to treat cholesterol disease.

istockphoto.com

Aegerion’s Juxtapid drug is used to treat cholesterol disease.

Continue reading below

Aegerion Pharmaceuticals Inc. rose on Tuesday and Wednesday even after it posted a wider net quarterly loss of $18.9 million amid higher expenses. Aegerion raised its revenue expectations for the year to reflect recent results from the launch of its genetic cholesterol-disease drug, Juxtapid, its sole product on the market. Aegerion raised its net revenue expectation to $30 million to $35 million, from earlier guidance of $15 million to $25 million.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week